x

Search for a diagnostic test

* (*) mandatory field

22 Result(s)

Filter by

Speciality(ies)/objective(s)

Technique(s)

Purpose(s)

Quality management

Country(ies)

Reset
Sort by

Caption : Accreditation =Accreditation
;

FRANCE

ILE-DE-FRANCE
LE KREMLIN-BICÊTRE

Accreditation
Pharmacogenetics analysis of CYP2C9 gene
CHU Paris-Sud - Hôpital de Bicêtre
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : PCR based techniques

FRANCE

HAUTS-DE-FRANCE
LILLE

Accreditation
Pharmacogenetics analysis of CYP2C9 gene
CHU de Lille - Centre de Biologie Pathologie Génétique
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Sequence analysis: entire coding region
Technique(s) : Sanger sequencing

GERMANY

Rheinland-Pfalz
INGELHEIM AM RHEIN

Accreditation
Pharmacogenetic analysis of CYP2C9 gene
Bioscientia Institut für Medizinische Diagnostik GmbH
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : PCR based techniques

GERMANY

Bayern
MARTINSRIED

Accreditation
Pharmacogenetic analysis of CYP2C9 gene
Zentrum für Humangenetik und Laboratoriumsdiagnostik (MVZ)
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : PCR based techniques

GERMANY

Hamburg
HAMBURG

Accreditation
Pharmacogenetic analysis of CYP2C9 gene
Labor Lademannbogen
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : Sanger sequencing

GERMANY

Hessen
FRANKFURT AM MAIN

Accreditation
Pharmacogenetic analysis of CYP2C9 gene
bio.logis Zentrum für Humangenetik
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Sequence analysis: entire coding region
Technique(s) : Sanger sequencing

SWITZERLAND

Suisse Romande
GENÈVE

Accreditation
Pharmacogenetic analysis of the CYP2C9 gene (variant *2 and *3)
Hôpitaux Universitaires de Genève HUG
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : PCR based techniques

GERMANY

Bayern
MÜNCHEN

Accreditation
Pharmacogenetic analysis of CYP2C9 gene
Pränatalmedizin München
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Sequence analysis: entire coding region, Deletion / Duplication analysis
Technique(s) : Sanger sequencing, MLPA based techniques

GERMANY

Nordrhein-Westfalen
KÖLN

Accreditation
Pharmacogenetic analysis of CYP2C9 gene
laboratoriumsmedizin köln - Dres. med. Wisplinghoff und Kollegen
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : Sanger sequencing, PCR based techniques

CZECH REPUBLIC

South Moravia
HODONIN

Accreditation
Pharmacogenetics analysis of the CYP2C9 gene
Chemila, spol. s r.o.
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis

NETHERLANDS

Zuid-Holland
ROTTERDAM

Accreditation
Pharmacogenetic analysis of CYP2C9 gene variants (variant *1, *2 and *3)
Erasmus MC - Erasmus Medisch Centrum
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : PCR based techniques

GERMANY

Nordrhein-Westfalen
BAD OEYNHAUSEN

Accreditation
Pharmacogenetic analysis of CYP2C9 gene
Ruhr-Universität Bochum
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : Sanger sequencing, PCR based techniques

NORWAY

Østlandet
OSLO

Accreditation
Pharmacogenetics analysis of CYP2C9 gene
Oslo Universitetssykehus HF, Rikshospitalet
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis

PORTUGAL

SUL
LISBOA

Pharmacogenetics analysis of CYP2C9 gene.
Faculdade de Medicina da Universidade de Lisboa
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis

PORTUGAL

SUL
LISBOA

Pharmacogenetics analysis of responses to warfarin treatment (VKORC1 and CYP2C9 genes)
Faculdade de Medicina da Universidade de Lisboa
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis

ITALY

CAMPANIA
NAPOLI

Pharmacogenetics analysis of the CYP2C9, VKORC1, CYP2D6 genes
Biotecnologie Avanzate Srl
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis, Mutation scanning/screening and sequence analysis of selected exons, Sequence analysis: entire coding region
Technique(s) : Sanger sequencing

CZECH REPUBLIC

South Bohemia
CESKE BUDEJOVICE

Pharmacogenetics analysis of the CYP2C9 gene
Hospital Ceské Budejovice
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis

CZECH REPUBLIC

Liberec
LIBEREC

Pharmacogenetics analysis of the CYP2C9 gene
Regional Hospital Liberec, Krajska nemocnice Liberec
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis

CZECH REPUBLIC

Plzen
PLZEN - BORY

Pharmacogenetics analysis of the CYP2C9 gene
Pilsen University Hospital, Fakultni nemocnice Plzen - areal Bory
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis

CZECH REPUBLIC

Plzen
PLZEN

Pharmacogenetics analysis of the CYP2C9 gene
Genomia s.r.o.
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis

SPAIN

Madrid
SAN SEBASTIÁN DE LOS REYES

Diagnosis of major susceptibility to oral antidiabetic drugs and vitamin K antagonists toxicity or dose selection (CYP2C9 gene)
LabGenetics - Laboratorio de Genética Clínica, S.L.
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis, Mutation scanning/screening and sequence analysis of selected exons, Sequence analysis: entire coding region
Technique(s) : Sanger sequencing

AUSTRIA

OBERÖSTERREICH
LINZ

Molecular genetic analysis of CYP2C9
Ordensklinikum Linz GmbH Elisabethinen
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : PCR based techniques